The efficacy of intralesional vitamin D3 injection in the treatment of cutaneous warts: A clinical therapeutic trial study.
- 2023-08
- Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) 29(8)
- Haider Al-Sabak
- Mohammed Al-Hattab
- Marwah Al-Rammahi
- Muhsin Al-Dhalimi
- PubMed: 37632174
- DOI: 10.1111/srt.13442
Study Design
- Type
- Clinical Trial
- Sample size
- n = 204
- Population
- 40 patients (14 men and 26 females) with 204 cutaneous warts
- Methods
- Intralesional injection of vitamin D3 solution (600,000 IU) at 0.2 mL per patient, up to 5 warts per session, every 2 weeks for a total of four times; patients instructed to forego any topical or oral medication
- Blinding
- Open-label
- Duration
- every 2 weeks for a total of four times
- Large Human Trial
Background
The human papillomavirus that causes warts is usually harmless, and it can infect any part of the skin or mucous membranes. Despite the availability of several treatments, warts often return, and scarring, pigmentation changes, and recurrence are all possible side effects.Aim
Intralesional vitamin D3 was employed as an immunotherapy for cutaneous warts in the current investigation.Materials and methods
In Al-Sadr Medical City in the city of Al-Najaf Al-Ashraf, a skin clinic conducted a therapeutic clinical experiment. A total of 204 cutaneous warts were examined in 40 patients (14 men and 26 females). Vitamin D3 solution of the dose (600 000 IU) was injected into the lesions' bases, with 0.2 mL per patient. Each session could only inject up to five warts. The injections were given every 2 weeks for a total of four times. Instructing patients to forego the use of any topical or oral medication was also a part of the protocol. Each patient was evaluated for recurrence risk before each therapy and then again 6 months later.Result and discussion
There was a wide range of patient ages in this study, from 20 months to 52 years. About 65% of the cases included females. When looking at the many kinds of warts, the most prevalent was the common wart (71.6%). After four treatments, a positive response was considered to have occurred when all lesions had disappeared, a partial response when more than half of the lesions had disappeared, and no reaction when less than half of the lesions had disappeared. The final tally was 81.9% for those who responded in whole, 11.3% for those who responded partially, and 6.9% for those who did not respond at all. Next-session complete response rates were 12.7%, 29.9%, 54.9%, and 81.9%, respectively. Thirteen people experienced adverse symptoms, most noticeably minor swelling and itching. Within 6 months of follow-up, warts had completely disappeared for all patients with a partial or modest response except one who had no reaction.Conclusion
Vitamin D3 administered intralesional is an effective and low-cost treatment for cutaneous warts.Research Insights
11.3% for those who responded partially
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 600,000 IU per session injected intralesionally every 2 weeks for 4 sessions
Within 6 months of follow-up, warts had completely disappeared for all patients with a partial or modest response except one who had no reaction
- Effect
- Beneficial
- Effect size
- Large
- Dose
- 600,000 IU per session injected intralesionally every 2 weeks for 4 sessions
The final tally was 81.9% for those who responded in whole
- Effect
- Beneficial
- Effect size
- Large
- Dose
- 600,000 IU per session injected intralesionally every 2 weeks for 4 sessions
Adverse Events Reported
Thirteen people experienced adverse symptoms, most noticeably minor swelling and itching.
- Finding
- Reported
- Grade
- mild
Thirteen people experienced adverse symptoms, most noticeably minor swelling and itching.
- Finding
- Reported
- Grade
- mild